


Chemical Science

rsc.li/chemical-science



ISSN 2041-6539

EDGE ARTICLE

Dingbin Liu *et al.*

Stimulus-responsive surface-enhanced Raman scattering:
a "Trojan horse" strategy for precision molecular diagnosis
of cancer



Cite this: *Chem. Sci.*, 2020, **11**, 6111

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 20th March 2020
Accepted 15th May 2020

DOI: 10.1039/d0sc01649g
rsc.li/chemical-science

Stimulus-responsive surface-enhanced Raman scattering: a “Trojan horse” strategy for precision molecular diagnosis of cancer†

Cai Zhang,^a Xiaoyu Cui, ^a Jie Yang,^a Xueguang Shao, ^a Yuying Zhang ^b and Dingbin Liu ^{*a}

Molecular diagnosis has played an increasingly important role in cancer detection. However, it remains challenging to develop an *in situ* analytical method capable of profiling the molecular phenotype of tumors for precision cancer diagnosis. A “Trojan horse” strategy based on stimulus-responsive surface-enhanced Raman scattering (SR-SERS) is reported here for selectively recording the comprehensive molecular information of tumors *in situ*, without resorting to destructive sample preparation and complex data analysis. This technique is employed to delineate the margin between tumors and normal tissues with high accuracy, and to further discriminate the molecular fingerprints of tumors in the early and late stages. Based on molecular profiling, we discovered that the signal ratios of fatty acid-to-phenylalanine could serve as promising indicators for identifying the primary tumors in different stages. This simple SR-SERS technique also provides a potential useful means for identifying tumor classifications or distinguishing primary and metastatic tumors.

Introduction

The tumor microenvironment (TME) is recognized as the “soil” of cancer that plays a critical role in tumor growth, metastasis, and prognosis.^{1,2} The TME constitutes a complex network of biospecies whose abnormal functions are highly associated with cancer development.³ Gaining access to the comprehensive molecular information of the TME could revolutionize molecular diagnosis and help physicians make accurate and timely decisions for clinical intervention.⁴ A number of analytical methods such as metabolomics,⁵ proteomics,⁶ gene sequencing,⁷ immunoassays,⁸ and mass spectrometry⁹ have been established for collecting the molecular information of tumors. However, all these techniques can only provide fragmented molecular information of the TME, which is unable to reflect the overall molecular changes. At present, obtaining the comprehensive molecular details of biological tissues relies on the coupling of multiple analytical methods, which are complicated, time-consuming, and costly. Moreover, these techniques often rely on the destructive preparation of target tissues into solutions, causing the loss of tissue's morphological

information.¹⁰ A non-destructive analytical method that can provide *in situ* comprehensive molecular signatures of the TME is highly required for the precision diagnosis of cancer.

Raman spectroscopy represents a biocompatible detection tool that provides unique vibrational bands for target molecules.¹¹ However, the extremely weak Raman signals of native biomolecules make this technique difficult for direct profiling of the TME molecular vibrations *in situ*. Surface-enhanced Raman scattering (SERS) has been proven to be a powerful strategy for enhancing the Raman scattering of a molecule when it is brought in close proximity to a metallic nanoparticle surface.¹²⁻²⁵ The detection sensitivity of SERS can be down to single-molecule levels.^{26,27} Thus, SERS has been utilized to analyze the molecular vibrations of different tissue types by coating the tissue surfaces with metal nanoparticles.²⁸ However, Raman signals on these tissues are “always-on”. As a result, it is rather difficult to directly discriminate the molecular vibrations between cancer and healthy tissues since they possess similar chemical compositions. There is lacking a strategy that can selectively amplify the biomolecular vibrations of tumor tissues *in situ* for precision cancer diagnosis.

Herein, we report a stimulus-responsive SERS (referred to as SR-SERS) probe, which functions like a Trojan horse, to specifically augment the vibrational signals of the TME for precision molecular diagnosis of cancer. This TME-specific SERS probe is designed based on a manganese dioxide-encapsulated gold nanoparticle (Au@MnO₂ NP, abbreviated as AM NP) core-shell structure. The AM NPs were assembled using a polyethylene glycol (PEG) layer to minimize non-specific

^aCollege of Chemistry, Research Center for Analytical Sciences, State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Molecular Recognition and Biosensing, Collaborative Innovation Center of Chemical Science and Engineering, Nankai University, Tianjin 300071, China. E-mail: liudb@nankai.edu.cn

^bSchool of Medicine, Nankai University, Tianjin 300071, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0sc01649g



protein adsorption in physiological environments. When the PEGylated AM NPs are introduced into the blood circulation, the PEG and MnO_2 shells isolate biomolecules from interacting with the Au NP core, thus turning off the SERS signals of the probe (Fig. 1a). After accumulation into the tumors by the enhanced permeability and retention (EPR) effect,²⁹ the AM NPs can be decomposed into the naked Au NPs and Mn^{2+} in the presence of acidic pH/ H_2O_2 species that are abundant in the TME. The freshly-exposed Au NPs are adsorbed by the native biomolecules, thus amplifying their Raman signals remarkably *in situ*. At the same time, the released Mn^{2+} offers intense T_1 -weighted magnetic resonance (MR) signals to report the location and morphological information of the TME. The proposed SR-SERS probes were applied to determining the margin between tumor and normal tissues with high accuracy. Further, we employed the SR-SERS technique to differentiate the overall molecular fingerprints of tumors in different growth stages.

Results and discussion

Synthesis and characterization

The AM NPs were synthesized with a simple *in situ* growth method, in which Au NPs were prepared as the core, followed by depositing MnO_2 shells. KMnO_4 and poly(allylamine hydrochloride) (PAH) act as the manganese source and reducing

agent, respectively.³⁰ The dosages of KMnO_4 and PAH were optimized to obtain a core–shell spherical structure (Fig. S1†).

We next characterized the as-obtained AM NPs with different analytical tools. The morphology of the AM NPs was first characterized by high-resolution transmission electron microscopy (HRTEM). Fig. 1b reveals that the AM NPs possess uniform core–shell structures with an Au core (54 ± 5 nm in diameter) wrapped by a MnO_2 shell with a thickness of 24 ± 2 nm. The core–shell structure of AM NPs was confirmed by energy-dispersive X-ray spectroscopy (EDS) mapping (Fig. 1c). The UV-vis spectra of the Au NPs, MnO_2 NPs, and AM NPs were recorded subsequently. The two typical absorption peaks of AM NPs at 380 and 595 nm are overlapped with the surface plasmon bands of MnO_2 and Au NP cores, respectively (Fig. 1d), validating the formation of AM NPs. X-ray photoelectron spectroscopy (XPS) was further employed to analyze the chemical composition of AM NPs. As shown in Fig. S2,† the O 1s spectrum has two peaks centered at 529.7 and 531.5 eV, which correspond to O 1s binding energies in the anhydrous compounds (Mn–O–Mn) and hydrated manganese (Mn–O–H) respectively. The binding energies for $\text{Mn} 2p_{1/2}$ and $\text{Mn} 2p_{3/2}$ are calculated to be 653.9 and 642.6 eV, respectively; while those for $\text{Au} 4f_{7/2}$ and $\text{Au} 4f_{5/2}$ are 83.9 and 87.6 eV, respectively.³¹ The loss of the SERS effect of AM NPs was assessed by incubating with Raman dyes and compared to that of the naked Au NPs. When the AM NPs




Fig. 1 Schematic illustration of the SR-SERS strategy and characterization of the AM NPs. (a) The design of the “Trojan horse” strategy based on SR-SERS for molecular diagnosis of cancer. The abundant $\text{H}_2\text{O}_2/\text{H}^+$ species in the TME trigger the release of Mn^{2+} and the naked Au NPs, which serve as T_1 contrast agents for MRI and SERS substrates to amplify the vibrational fingerprints of the native biomolecules in the tumor, respectively. (b) HRTEM image of AM NPs. (c) HAADF-STEM image of AM NPs and the EDX elemental mapping of the Au core, MnO_2 shell, and the merged image. (d) UV-vis spectra of Au NPs, MnO_2 NPs, and the AM NPs.



were incubated with rhodamine 6G (R6G, 0.2 μ M), no Raman signals can be detected; while the naked Au NPs (\sim 55 nm in diameter) can enhance the intensity of the same concentration of R6G for more than 4 orders of magnitude (Fig. S3†). This result implies that the MnO_2 shell can inhibit the SERS effect of the Au NP core on the free dyes.

To enhance the stability and biocompatibility of the yielded AM NPs, the NP surfaces were wrapped with PEG chains *via* a layer-by-layer coating strategy (Scheme S1†). The PEG coating was characterized by Fourier-transform infrared spectroscopy, which shows the characteristic C–O–C bands (1179 cm^{-1}) of PEG in the spectrum (Fig. S4†). The zeta potential of the AM NPs was determined to be 5.1 mV due to the presence of amino

groups in PAH, and the NPs became negatively charged after functionalization with polyacrylic acid (PAA) and NH_2 -PEG (Fig. S5†). DLS analysis indicates that, before and after modification with PEGs, the average hydrodynamic diameters of AM NPs were measured to be 106 and 140 nm, respectively (Fig. S6†). All the characterization experiments confirmed the formation of AM NPs as well as those coated with PEGs.

Acidic pH/ H_2O_2 -dependent AM NP decomposition

The specific decomposition of the MnO_2 shells was visualized by the naked eye, accompanied by the change of UV-vis absorption spectra in different media. It is well known that







Fig. 2 Characterization of the acidic pH/ H_2O_2 -responsive AM NPs and SERS/MR turn on ability. (a) UV-vis spectra and corresponding color of the solutions containing Au NPs, MnO_2 NPs, AM NPs, and the AM NPs decomposed by the acidic pH/ H_2O_2 solution (pH 6.5, H_2O_2 : 100 μM). (b) TEM images of AM NPs before and after treatment with acidic buffer solution (pH 6.5), neutral pH/ H_2O_2 solution (pH 7.4, H_2O_2 : 100 μM) or acidic pH/ H_2O_2 solution (pH 6.5, H_2O_2 : 100 μM) for 5, 10, and 30 min. (c) T_1 -Weighted MR imaging and the corresponding T_1 relaxation rates (r_1) (d) of varying concentrations of AM NPs in solutions with different pH values (pH 6.5 and 7.4) in the absence or presence of H_2O_2 (0.5 mM). (e) Raman spectra of various biomolecules in AM NP solutions (0.6 nM) that were pretreated with an acidic pH/ H_2O_2 mixture and compared to those pretreated with pH 7.4 buffer. All the spectra were collected with a confocal Raman spectrometer using 633 nm (3 mW) laser excitation. Data acquirement time, 10 s. 7 different sets of SERS spectra were recorded for each kind of biomolecule (in gray), while the average spectra for the activated and silent signals are displayed in red and blue, respectively.



the TME is characteristic of acidic pH (6.2–6.9) and high-level H_2O_2 ($\sim 100 \mu\text{M}$),³² which possess high reactivity with MnO_2 to release Mn^{2+} . As shown in Fig. 2a, when the AM NPs were immersed in acidic pH/ H_2O_2 solution (pH 6.5, H_2O_2 : 100 μM), the color of the solution changed from dark-green to red in 5 min. In parallel, the absorption peak at 380 nm disappeared, along with the appearance of an absorption peak at around 550 nm that is assigned to the 55 nm naked Au NPs (Fig. S7†). The changes of both solution color and corresponding UV-vis spectra indicate the rapid decomposition of the MnO_2 shells and the production of the naked Au NPs. In contrast, the UV-vis absorption spectra of AM NPs showed a trivial change in either H_2O_2 solution or pH 6.5 buffer solution in 30 min (Fig. S8†). The TEM images further demonstrated the entire decomposition of the MnO_2 shells after treatment with acidic pH/ H_2O_2 solution for 30 min (Fig. 2b). However, the core–shell structures of AM NPs still kept intact after treatment with acidic solution alone or neutral pH/ H_2O_2 solution. These results demonstrate that the MnO_2 shells of AM NPs can be specifically decomposed by the synergistic effect of H^+ and H_2O_2 . The reaction between MnO_2 and H_2O_2 produces the intermediate Mn-oxo-hydroxide (MnOOH), which reacts with H^+ to generate Mn^{2+} and O_2 .^{33–38} The following reactions illustrate the acidic pH/ H_2O_2 -triggered hydrolysis of the MnO_2 shell:



Acidic pH/ H_2O_2 -activated turn-on MRI of AM NPs

Since Mn^{2+} is an excellent T_1 MR contrast agent,³⁹ we observed the concentration-dependent brightening effect of AM NPs for T_1 -weighted MR imaging in the acidic pH/ H_2O_2 solution, whereas the MR contrast effect under the other three conditions appeared to be much weaker (Fig. 2c). The enhanced T_1 signal intensities of these samples were quantified by calculating the T_1 relaxivity (r_1). Fig. 2d shows that the r_1 of the AM NPs was as high as $11.97 \text{ mM}^{-1} \text{ s}^{-1}$ in the acidic pH/ H_2O_2 solution owing to the decomposition of MnO_2 shells into the paramagnetic Mn^{2+} . In contrast, the r_1 values of the AM NPs under the other conditions were much smaller (0.11 – $0.81 \text{ mM}^{-1} \text{ s}^{-1}$). These results indicated the superior acidic pH/ H_2O_2 -activated MR imaging ability of the AM NPs.

Acidic pH/ H_2O_2 -activated Raman enhancement of AM NPs

To verify the SR-SERS effect of AM NPs *in vitro*, the AM NPs (0.02 nM) were pretreated with acidic pH/ H_2O_2 solution or neutral buffer solution (as control) for 30 min and centrifuged to 0.6 nM (6000 rpm, 2 min) and then incubated with several kinds of common biomolecules including bovine serum albumin (BSA, 12 mg mL^{-1}), nicotinamide adenine dinucleotide (NADH, 1 mg mL^{-1}), phenylalanine (3 mg mL^{-1}), glucose (12 mg mL^{-1}),

nucleic acid (TCCATGACGTTCTGACGTT, 0.3 mg mL^{-1}), and ATP (5 mg mL^{-1}) respectively at their optimized concentrations. The Raman fingerprint signals of the biomolecules were dramatically enhanced after incubation with AM NPs which had been pretreated with acidic pH/ H_2O_2 solution (Fig. 2e). Under the same spectral recording conditions, all the biomolecules remained silent when they were incubated with AM NPs pretreated with pH 7.4 buffer alone. The results imply that the AM NPs are able to report the comprehensive Raman fingerprints of biomolecules after decomposition of the MnO_2 shells to release the naked Au NPs in the TME.

TME-activated MR imaging and SERS detection *in vivo*

Encouraged by the acidic pH/ H_2O_2 -responsive MR and SERS effects *in vitro*, we then evaluated the feasibility of PEGylated AM NPs for TME-activated MR imaging and SERS detection *in vivo*. After intratumoral injection of the PEGylated AM NPs (100 μL , 1 mg mL^{-1}), the MR signals of the tumors became intense (Fig. S9a–c†). As a comparison, when the same amount of PEGylated AM NPs was injected into normal subcutaneous tissues, the MR signals had no noticeable change. This observation suggests that the AM NPs possess outstanding contrast effects resulting from the rapid, specific decomposition of MnO_2 shells into Mn^{2+} in the tumor sites. Besides, the Raman intensity of tumor tissues was much higher than that of normal tissues after treatment with the PEGylated AM NPs, which was attributed to the exposure of the naked Au NP cores to the TME that dramatically amplified the Raman signals of the native biomolecules (Fig. S9d†). However, the Raman signals in the normal tissue were virtually undetectable, most likely due to the inertness of the AM NPs in the neutral environments. These results indicate that the PEGylated AM NPs may allow tumor-specific turn-on MR imaging and label-free SERS detection.

The superior TME responsiveness of the dual turn-on MRI/SERS probes *via* intratumoral injection motivated us to explore the MRI and SERS performance *in vivo*. 200 μL of 1 mg mL^{-1} PEGylated AM NP solution was intravenously injected into a tumor-bearing mouse, and then the specific MR images were collected using a 3.0 T clinical MRI scanner. T_1 contrast enhancement of the tumor was observed gradually after intravenous injection (Fig. 3a and b). The highest enhancement of MRI signals was found at 4 h post-injection. These results demonstrated the excellent activated MR imaging capability of the PEGylated AM NPs in tumors. The TME-activated MRI holds great promise for monitoring the location and morphology of tumors with high spatial resolution.

TME-activated SERS detection *ex vivo*

To study the comprehensive SERS fingerprinting signatures of the native biomolecules in the tumor sites, the probe-administered mice were sacrificed at 4 h post-injection. Subsequently, the tumors and surrounding normal tissues were cut out, then sliced and fixed on glass slides. The Raman spectra and mapping images of the tissue slices were recorded using a confocal Raman microscope in a non-invasive fashion. Fig. 3c shows that the Raman signals of the native biomolecules




Fig. 3 *In vivo* MRI and *ex vivo* imaging of the TME using the SR-SERS strategy. (a) The photo of a tumor-bearing mouse that was intravenously injected with PEGylated AM NPs (200 μ L, 1 mg mL^{-1}). (b) MR imaging of the tumor model after intravenous injection with PEGylated AM NPs (200 μ L, 1 mg mL^{-1}) at different time points and corresponding quantitative T_1 -weighted MR signals of the tumors derived from six different mice (error bars). (c) Raman spectra of the native biomolecules in the tumor and the surrounding normal tissues ($n = 35$) after intravenous injection with the PEGylated AM NPs. The spectra were recorded using 633 nm (3 mW) laser excitation (acquisition time 8 s), while the mean spectra for the tumor and normal signals are displayed in red and blue, respectively. (d) Raman mapping images that were recorded via 6 channels, which correspond to the bands at 662, 747, 1000, 1173, 1250, and 1444 cm^{-1} respectively. (e) Bright-field image of the tissue and that merged with the multiple Raman mapping channels in (d). (f) H&E-staining image of (e) scale bars: 10 μm .

in the tumor tissues were much higher than those in the surrounding normal tissues. Based on this observation, we attempted to determine the boundary between the tumor and normal tissues by means of Raman mapping. Accurate delineation of the margin between tumors and normal tissues is extremely important for tumor resection in the clinic.^{40,41} Through mapping the tissues with multiple channels that are assigned to various native biospecies in the tumors (Fig. 3d), strong Raman signals can be observed in the tumor site but are undetectable in the neighboring normal tissues, providing a very clear boundary between the tumor and normal tissues (Fig. 3e). Impressively, the boundary delineated by Raman mapping correlated well with that determined by hematoxylin and eosin (H&E) staining (Fig. 3f). In contrast, if no probes were administered, the Raman intensities of the native biomolecules in both tumor and the surrounding normal tissues appeared to be quite weak, and no boundary was observed between the two types of tissues (Fig. S10†). These results verified the specific Raman enhancement effect of the PEGylated AM NPs towards

tumors. The TME-specific comprehensive molecular profiling ability of the SR-SERS probe makes it promising for precision cancer diagnosis. Additionally, the TEM images in Fig. S11† show that the AM NPs were decomposed into naked Au NPs in the tumor tissues, confirming the TME-triggered SERS of the native biomolecules.

We further wanted to apply the PEGylated AM NPs to discriminating the Raman fingerprints of primary tumors with different growth periods, where the early growth group was less than 4 days and the late growth group was more than 14 days after transplantation of tumor cells. Fig. 4a shows that the T_1 -weighted tumors at different growth periods exhibit spectral changes in specific bands (Fig. 4b and c), indicating the diverse expression and distribution of the native biomolecules in tumors at different growth periods. Note that the mean spectra for each tumor at different growth periods were obtained from 420 spectra randomly chosen in different tumor slices. In detail, the Raman peaks at 747, 855, 941, 1173, 1250, 1300, 1365, 1396, 1444, 1579 and 1657 cm^{-1} showed distinctive changes in






Fig. 4 MR imaging, Raman spectroscopic detection, and metabolomics study of primary tumors in different growth stages. (a) MR images of tumors in different growth stages after intravenous injection with PEGylated AM NPs ($200 \mu\text{L}$, 1 mg mL^{-1}) for 4 h. (b) The mean Raman spectra of the tumors in different growth stages. The spectra for each tumor at different growth periods were recorded from seven parallel tumor-bearing mice. Each tumor was cut into multiple layers of slices with a thickness of $10 \mu\text{m}$, where the Raman spectra from three slices collected near the middle of tumors were recorded. The average spectra of 20 different single spectra were randomly recorded from each tumor slice using 633 nm (3 mW) laser excitation (acquisition time 8 s). Thus, the mean spectra for each tumor at different growth periods were collected from 420 different spectra. Blue, amino acids or proteins; red, carbohydrates; yellow, fatty acids; purple, nucleic acids or nucleotide; and green, metabolites. (c) SERS intensity ratios of peaks at 1444 and 1000 cm^{-1} for the tumor tissues in different growth periods, which correspond to the expression ratios of fatty acids and phenylalanine ($p < 0.001$). (d) PCA of the Raman spectral distribution of the tumor tissues at different growth periods in PC1–PC2. (e) Heat map for the ratios of fatty acid-to-phenylalanine for the tumors in different growth stages that were detected by gas chromatography-time-of-flight mass spectrum (GC-TOF/MS). The MS data were collected from six parallel samples of the tumors in the two groups. (f) PCA analysis of metabolites of the primary tumor tissues in different growth periods.

spectral intensity (Table 1).^{42–46} Among them, the peaks at 855 and 941 cm^{-1} are assigned to carbohydrates (red bars),^{46,47} the peaks at 1300 , 1444 and 1657 cm^{-1} belong to fatty acids (yellow bars),⁴⁵ and the peaks at 747 , 1173 , and 1365 cm^{-1} are related to lactic acids, urea, and creatinine, respectively (green bars).^{48–51} After comparing the Raman spectra of tumors in the two groups, we found that the intensity ratios of the peaks at 1444 and 1000 cm^{-1} have a significant difference. In detail, the intensity ratio in the early growth stage was much higher than that in the late growth stage ($p < 0.001$), which may be linked to the differences in the energy metabolism of the tumors in different growth stages. As shown in Fig. S12,† the SERS spectra of phenylalanine and two types of fatty acids (oleic acid and stearic acid) were determined; the spectra further demonstrated

the Raman peaks at 1000 and 1444 cm^{-1} related to phenylalanine and fatty acids respectively.

We further made use of principal component analysis (PCA) to classify the Raman spectra of the tumors in different growth stages. PCA is a statistical tool that compresses complex multivariate data into fewer dimensions, by which an overview of data is illustrated in a two- or three-dimensional plane. The distribution of the Raman spectra among the tumors in different groups is illustrated in the PC1–PC2 subspace (Fig. 4d). The results show that the most Raman spectra of the tumors in the two groups could be distinguished. These observations suggest that the new SR-SERS technique has the potential to differentiate the molecular fingerprints of tumors at different growth periods.

Table 1 Assignment of SERS spectral bands in Fig. 4b

Shift (cm ⁻¹)	Component	SERS band assignment
662	Protein	C–S stretching mode of cysteine
747	Metabolite	Lactic acid
795	Protein	L-Serine
827	Protein	Tyrosine
855	Carbohydrates	Monosaccharides and disaccharides
941	Carbohydrates	C–O–C
1000	Protein	Phenylalanine
1103	Protein	Amide III and other groups
1173	Metabolite	Urea
1250	Nucleic acid	Guanine, cytosine (NH ₂)
1300	Fatty acid	CH ₂ twisting modes
1335	Protein	CH ₃ CH ₂ wagging
1365	Metabolite	Creatinine
1396	Nucleic acid	Inosine
1444	Fatty acid	CH ₂ bending mode
1579	Nucleic acid	Ring breathing modes in the DNA bases
1605	Protein	Phenylalanine
1657	Fatty acid	$\nu(C=C)$

To validate the Raman intensity ratio changes of tumor tissues analyzed by the SR-SERS probes, a metabolomics study was carried out with the same set of samples by gas chromatography-time-of-flight mass spectrum (GC-TOF/MS) (Fig. 4e). The results of fatty acid/phenylalanine changes obtained from the metabolomics were consistent with the semi-quantitative SR-SERS results. Therefore, the ratio of fatty acid-to-phenylalanine has great potential to serve as an indicator for growth stages of primary tumors particularly in the early growth stages. Furthermore, the PCA analysis of the metabolites in the tumors at different growth stages (Fig. 4f) indicated tremendous differences, which was similar to the Raman profiling results.

Biodistribution of PEGylated AM NPs *in vivo*

To study the biodistribution of the PEGylated AM NPs *in vivo*, the tumor and major organs (heart, liver, spleen, kidney and brain) of the mice ($n = 7$) that had been treated with PEGylated AM NPs were collected at different time points (4 h, 1 day and 7 days) post-injection. After digestion in aqua regia, the tissue samples were analyzed by ICP-OES. The results in Fig. S13[†] showed that the majority of the Au elements accumulated in the liver and spleen within 4 h and 1 day. The elemental Au was also enriched in the tumor, heart, and kidney at 4 h post-injection, while no detectable Au elements were taken up by the brain. After 7 days, the Au amounts distributed in the organs approached that of the control. On the other hand, the Mn uptake in the kidney and liver was significantly high at 4 h post-injection, and a considerable amount of Mn was also accumulated in the tumor, heart, and spleen, while there was still no Mn uptake in the brain. One day later, most of the Mn elements were cleared out from the organs except for the kidney, which may correspond to the renal metabolism of the Mn ions. After 7 day post-injection, the Mn levels in all the organs declined to that of the control, indicating that the Mn elements had been cleared out completely. These results implied that the

PEGylated AM NPs can be metabolized and cleared out from the body in one week.

Assessment of *in vivo* toxicity

We finally evaluated the chemical stability and biocompatibility of PEGylated AM NPs. The TEM images show that the core–shell NPs kept intact after incubation in the freshly-collected mouse serum for 4 h (Fig. S14[†]). The biocompatibility of the NPs was estimated by measuring the body weight, H&E analysis of major organs and biochemical analysis of blood of the mice that were intravenously injected with the PEGylated AM NPs (200 μ L, 1 mg mL⁻¹). The body weight of the mice increased gradually with the growth of the mice, showing no discernible difference with the control group in 30 days (Fig. S15[†]). Besides, H&E analysis results indicated that there was no visible tissue damage in the major organs (heart, liver, spleen, lung, kidney, brain, and thymus) of the mice after the treatment with the nanoparticle probes (Fig. 5a). The biochemical analysis results show that most of the parameters in the AM NP-treated group had similar levels to those of the control group after one-day post-injection, except for AST and ALT whose levels were elevated (Fig. 5b). However, the levels of AST and ALT declined to that of the control group on the 7th day, while other parameters in the experimental group remained persistent during the NP treatment.

Since the cytotoxic effect of the AM NPs on the immune system can be reflected by the change of the immune cells in the blood, we counted the immune cells after intravenous injection of the NPs. In detail, after injection of the PEGylated AM NPs, the blood of the mice ($n = 7$) was collected at different time points for counting the immune cells including lymphocytes, monocytes, and neutrophil granulocytes. As shown in Fig. 5c, the numbers of the three types of cells on the 1st and 7th day post-injection were approximate to those of the control group. Besides, the peripheral mononuclear cells including lymphocytes and monocytes were isolated from the blood for apoptosis analysis by fluorescent-activated cell sorting (FACS). Fig. 5d shows that only a few numbers of cells in the early apoptosis (FITC-labeled) or necrosis (PI-labeled) were detected within both 4 h and 1 day, which are comparable to that of the control without any treatment. These results revealed that the PEGylated AM NPs had no apparent adverse effect on the immune cells.

To further verify the neurotoxicity of the PEGylated AM NPs, brain sections from the mice treated with the NPs were analyzed with a TUNEL (TdT-mediated dUTP nick end labeling) staining kit (Roche). The fragmented DNA could be stained through labeling the 3'-hydroxyl termini. Thus, apoptotic cells in the brain sections would be labeled in green. Fig. S16[†] reveals that no obvious TUNEL-positive cells appeared in the brain tissues of the mice intravenously injected with PEGylated AM NPs for 1 and 7 days, which was similar to the control group. The result demonstrates that the PEGylated AM NPs possess negligible neurotoxicity. All of the preliminary *in vivo* toxicity results revealed that the PEGylated AM NPs have excellent biocompatibility, which is crucially important to their biological and biomedical applications.






Fig. 5 *In vivo* toxicity evaluation of the PEGylated AM NPs. (a) Histopathological results of different organs in the mice after they were intravenously injected with PEGylated AM NPs (200 μ L, 1 mg mL^{-1}) for 1 and 7 days and that without any treatment. Scale bar, 100 μm . (b) The blood levels of the liver function markers (AST, ALT, ALB, T-Bil, D-Bil, GGT) and the kidney function markers (BUN, CR, UA) in the mice treated with and without PEGylated AM NPs (200 μ L, 1 mg mL^{-1}) for 1 and 7 days. (c) Cell counting of lymphocytes (Lymph), monocytes (Mon) and neutrophil granulocytes (Gran) from the peripheral blood of mice intravenously injected with PEGylated AM NPs (200 μ L, 1 mg mL^{-1}) for 1 and 7 days and that without any treatment was set as control. Error bars represent the standard deviations between seven parallel mice. (d) Flow cytometry analysis for measuring the apoptotic peripheral blood mononuclear cells collected from the mice exposed to the PEGylated AM NPs (200 μ L, 1 mg mL^{-1}) for 4 h and 1 day. The peripheral blood mononuclear cells of the mice without any treatment were set as control.

Conclusions

In summary, we have developed a powerful yet biocompatible “Trojan horse” SR-SERS nanoprobe to augment the vibrational fingerprints of tumors *in situ* for precision molecular diagnosis of cancer. The proposed SR-SERS strategy is, to our knowledge, the first approach that is capable of profiling the molecular fingerprints of tumor tissues selectively without destruction of the samples. The “Trojan horse” SR-SERS approach shows at least two advantages over traditional molecular diagnostic tools. First, the SR-SERS probes can only be activated by the TME while remained silent in other tissues, thus showing extremely high specificity to tumors. Second, the TME-triggered exposure of the naked Au NPs to native biomolecules could significantly amplify their overall Raman fingerprints to offer comprehensive molecular information, rather than to provide fragmented information as traditional molecular profiling approaches do. The high specificity of the SR-SERS probes in

the TME made this new technique extremely potent in delineating the margin between tumors and healthy tissues, which may greatly facilitate precision tumor resection. Furthermore, the TME-responsive SERS spectra of tumors in different growth stages provided useful information that may reveal molecular changes of energy metabolism and genetic mutants in the process of tumor development, showing great potential in studying tumor growth, differentiation, and migration especially in combination with the Mn^{2+} -based MRI. Impressively, the molecular profiling results showed that fatty acid/phenylalanine is a promising indicator of primary tumors in different growth stages.

To achieve diagnostic recommendations in clinical settings, long-term biosafety of the PEGylated AM NPs should be demonstrated with large data. To demonstrate the easy generalizability of the “Trojan horse” strategy as a cancer diagnostic tool, we plan to bring this technique into profiling molecular signatures in tumor classifications as well as those under

different treatments. To minimize the amount of SR-SERS probes used for cancer diagnosis, we will focus on the enhancement of SERS sensitivity by using anisotropic nanoparticles such as nanocubes, nanorods, nanostars, nano-triangles, and core/satellite nanoparticles, to name a few, because such nanostructures show much more intense field enhancements for SERS than single spherical nanoparticles.^{52–57}

Ethical statement

All animal studies were performed in compliance with the institutional guidelines made by the Tianjin Committee of Use and Care of Laboratory Animals and the overall regulations approved by the Animal Ethics Committee of Nankai University.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This study was supported by the National Key R&D Program of China (2019YFA0210103), the National Natural Science Foundation of China (21775075 and 21977053), and the Fundamental Research Funds for Central Universities (China). We are grateful to Professor Xiaobing Zhang from Hunan University for his enthusiastic discussion about the data.

Notes and references

- 1 B. Mlecnik, G. Bindea, A. Kirilovsky, H. K. Angell, A. C. Obenauf, M. Tosolini, S. E. Church, P. Maby, A. Vasaturo, M. Angelova, T. Fredriksen, S. Mauger, M. Waldner, A. Berger, M. R. Speicher, F. Pages, V. Valge-Archer and J. Galon, *Sci. Transl. Med.*, 2016, **8**, 327ra26.
- 2 X. Huang, J. Song, B. C. Yung, X. Huang, Y. Xiong and X. Chen, *Chem. Soc. Rev.*, 2018, **47**, 2873–2920.
- 3 A. Sharma, M.-G. Lee, H. Shi, M. Won, J. F. Arambula, J. L. Sessler, J. Y. Lee, S.-G. Chi and J. S. Kim, *Chem.*, 2018, **4**, 2370–2383.
- 4 X. H. Fang and W. H. Tan, *Acc. Chem. Res.*, 2010, **43**, 48–57.
- 5 Z. Wang, B. Cui, F. Zhang, Y. Yang, X. Shen, Z. Li, W. Zhao, Y. Zhang, K. Deng, Z. Rong, K. Yang, X. Yu, K. Li, P. Han and Z.-J. Zhu, *Anal. Chem.*, 2019, **91**, 2401–2408.
- 6 G. Yanovich, H. Agmon, M. Harel, A. Sonnenblick, T. Peretz and T. Geiger, *Cancer Res.*, 2018, **78**, 6001–6010.
- 7 H.-M. Lu, S. Li, M. H. Black, S. Lee, R. Hoiness, S. Wu, W. Mu, R. Huether, J. Chen, S. Sridhar, Y. Tian, R. McFarland, J. Dolinsky, B. T. Davis, S. Mexal, C. Dunlop and A. Elliott, *JAMA Oncol.*, 2019, **5**, 51–57.
- 8 J. Shan and Z. Ma, *Microchim. Acta*, 2017, **184**, 969–979.
- 9 P. Saudemont, J. Quanico, Y.-M. Robin, A. Baud, J. Balog, B. Fatou, D. Tierny, Q. Pascal, K. Minier, M. Pottier, C. Focsa, M. Ziskind, Z. Takats, M. Salzet and I. Fournier, *Cancer Cell*, 2018, **34**, 840–851.
- 10 M. V. Yezhelyev, A. Al-Hajj, C. Morris, A. I. Marcus, T. Liu, M. Lewis, C. Cohen, P. Zrazhevskiy, J. W. Simons, A. Rogatko, S. Nie, X. Gao and R. M. O'Regan, *Adv. Mater.*, 2007, **19**, 3146–3151.
- 11 S. Schluecker, *Angew. Chem., Int. Ed.*, 2014, **53**, 4756–4795.
- 12 S. Kim, T. G. Kim, S. H. Lee, W. Kim, A. Bang, S. W. Moon, J. Song, J. H. Shin, J. S. Yu and S. Choi, *ACS Appl. Mater. Interfaces*, 2020, **12**, 7897–7904.
- 13 Z. Cheng, N. Choi, R. Wang, S. Lee, K. C. Moon, S. Y. Yoon, L. X. Chen and J. Choo, *ACS Nano*, 2017, **11**, 4926–4933.
- 14 J. Wang, D. W. Liang, J. Feng and X. J. Tang, *Anal. Chem.*, 2019, **91**, 11045–11054.
- 15 Y. Q. Wang, B. Yan and L. X. Chen, *Chem. Rev.*, 2013, **113**, 1391–1428.
- 16 C. Zong, M. X. Xu, L. J. Xu, T. Wei, X. Ma, X. S. Zheng, R. Hu and B. Ren, *Chem. Rev.*, 2018, **118**, 4946–4980.
- 17 Y. X. Zou, S. Q. Huang, Y. X. Liao, X. P. Zhu, Y. Q. Chen, L. Chen, F. Liu, X. X. Hu, H. J. Tu, L. Zhang, Z. K. Liu, Z. Chen and W. H. Tan, *Chem. Sci.*, 2018, **9**, 2842–2849.
- 18 H. W. Wang, Y. F. Cui, J. F. Wang, S. Liu, X. Zhang, X. L. Song, Y. Wang, J. D. Huang and J. H. Yu, *Sens. Actuators, B*, 2019, **287**, 535–543.
- 19 H. Karabeben, R. Huang, P. Iacono, J. M. Samii, K. Pitter, E. C. Holland and M. F. Kircher, *ACS Nano*, 2014, **8**, 9755–9766.
- 20 A. Oseledchyk, C. Andreou, M. A. Wall and M. F. Kircher, *ACS Nano*, 2017, **11**, 1488–1497.
- 21 L. A. Lane, X. Qian and S. Nie, *Chem. Rev.*, 2015, **115**, 10489–10529.
- 22 S. Harmsen, M. A. Bedics, M. A. Wall, R. Huang, M. R. Detty and M. F. Kircher, *Nat. Commun.*, 2015, **6**, 6570.
- 23 S. Pal, A. Ray, C. Andreou, Y. Zhou, T. Rakshit, M. Włodarczyk, M. Maeda, R. Toledo-Crow, N. Berisha, J. Yang, H.-T. Hsu, A. Oseledchyk, J. Mondal, S. Zou and M. F. Kircher, *Nat. Commun.*, 2019, **10**, 1926.
- 24 M. F. Kircher, A. de la Zerda, J. V. Jokerst, C. L. Zavaleta, P. J. Kempen, E. Mittra, K. Pitter, R. Huang, C. Campos, F. Habte, R. Sinclair, C. W. Brennan, I. K. Mellinghoff, E. C. Holland and S. S. Gambhir, *Nat. Med.*, 2012, **18**, 829–834.
- 25 Y. Zhang, Y. Gu, J. He, B. D. Thackray and J. Ye, *Nat. Commun.*, 2019, **10**, 1926.
- 26 S. Nie and S. R. Emory, *Science*, 1997, **275**, 1102–1106.
- 27 K. Kneipp, Y. Wang, H. Kneipp, L. T. Perelman, I. Itzkan, R. R. Dasari and M. S. Feld, *Phys. Rev. Lett.*, 1997, **78**, 1667–1670.
- 28 D. Cialla-May, X. S. Zheng, K. Weber and J. Popp, *Chem. Soc. Rev.*, 2017, **46**, 3945–3961.
- 29 H. Maeda, J. Wu, T. Sawa, Y. Matsumura and K. Hori, *J. Controlled Release*, 2000, **65**, 271–284.
- 30 X. Yi, L. Chen, X. Zhong, R. Gao, Y. Qian, F. Wu, G. Song, Z. Chai, Z. Liu and K. Yang, *Nano Res.*, 2016, **9**, 3267–3278.
- 31 Y. Ling, D. Zhang, X. Cui, M. Wei, T. Zhang, J. Wang, L. Xiao and Y. Xia, *Angew. Chem., Int. Ed.*, 2019, **58**, 1–6.
- 32 F. Gong, N. Yang, X. Wang, Q. Zhao, Q. Chen, Z. Liu and L. Cheng, *Nano Today*, 2020, **32**, 100851.
- 33 Q. Chen, L. Feng, J. Liu, W. Zhu, Z. Dong, Y. Wu and Z. Liu, *Adv. Mater.*, 2016, **28**, 7129–7136.



34 B. Li, Z. Gu, N. Kurniawan, W. Chen and Z. P. Xu, *Adv. Mater.*, 2017, **29**, 1700373.

35 C.-C. Huang, W.-T. Chia, M.-F. Chung, K.-J. Lin, C.-W. Hsiao, C. Jin, W.-H. Lim, C.-C. Chen and H.-W. Sung, *J. Am. Chem. Soc.*, 2016, **138**, 5222–5225.

36 G. Yang, L. Xu, Y. Chao, J. Xu, X. Sun, Y. Wu, R. Peng and Z. Liu, *Nat. Commun.*, 2017, **8**, 902.

37 Z. L. Zhao, H. H. Fan, G. F. Zhou, H. R. Bai, H. Liang, R. W. Wang, X. B. Zhang and W. H. Tan, *J. Am. Chem. Soc.*, 2014, **136**, 11220–11223.

38 M. Song, T. Liu, C. Shi, X. Zhang and X. Chen, *ACS Nano*, 2016, **10**, 633–647.

39 P. Mi, D. Kokuryo, H. Cabral, H. Wu, Y. Terada, T. Saga, I. Aoki, N. Nishiyama and K. Kataoka, *Nat. Nanotechnol.*, 2016, **11**, 724–730.

40 S. Harmsen, R. Huang, M. A. Wall, H. Karabeber, J. M. Samii, M. Spaliviero, J. R. White, S. Monette, R. O'Connor, K. L. Pitter, S. A. Sastra, M. Saborowski, E. C. Holland, S. Singer, K. P. Olive, S. W. Lowe, R. G. Blasberg and M. F. Kircher, *Sci. Transl. Med.*, 2015, **7**, 271ra77.

41 Y. Qiu, Y. Zhang, M. Li, G. Chen, C. Fan, K. Cui, J.-B. Wan, A. Han, J. Ye and Z. Xiao, *ACS Nano*, 2018, **12**, 7974–7985.

42 J. K. Lim and S.-W. Joo, *J. Electroanal. Chem.*, 2007, **605**, 68–72.

43 U. K. Sarkar, *J. Mol. Struct.*, 2013, **1045**, 42–46.

44 G. Kister, G. Cassanas and M. Vert, *Polymer*, 1998, **39**, 267–273.

45 K. Kochan, H. Peng, E. S. H. Gwee, E. Izgorodina, V. Haritos and B. R. Wood, *Analyst*, 2019, **144**, 901–912.

46 A. C. S. Talari, Z. Movasaghi, S. Rehman and I. U. Rehman, *Appl. Spectrosc. Rev.*, 2015, **50**, 46–111.

47 M. Dudek, G. Zajac, E. Szafraniec, E. Wiercigroch, S. Tott, K. Malek, A. Kaczor and M. Baranska, *Spectrochim. Acta, Part A*, 2019, **206**, 597–612.

48 A. Liang, H. Wang, D. Yao and Z. Jiang, *Food Chem.*, 2019, **271**, 39–46.

49 H. Zhang, G. Li, S. Li, L. Xu, Y. Tian, A. Jiao, X. Liu, F. Chen and M. Chen, *Appl. Surf. Sci.*, 2018, **457**, 684–694.

50 Y. Lu, C. Wu, R. You, Y. Wu, H. Shen, L. Zhu and S. Feng, *Biomed. Opt. Express*, 2018, **9**, 4988–4997.

51 C. J. Saatkamp, M. L. de Almeida, J. A. Martins Bispo, A. L. Barbosa Pinheiro, A. B. Fernandes and L. Silveira Jr, *J. Biomed. Opt.*, 2016, **21**, 037001.

52 D. M. Solis, J. M. Taboada, F. Obelleiro, L. M. Liz-Marzan and F. Javier Garcia de Abajo, *ACS Photonics*, 2017, **4**, 329–337.

53 T. Vi, B. Walkenfort, M. Koenig, M. Salehi and S. Schluecker, *Angew. Chem., Int. Ed.*, 2019, **58**, 442–446.

54 A. Kumar, S. Kim and J.-M. Nam, *J. Am. Chem. Soc.*, 2016, **138**, 14509–14525.

55 J.-E. Park, Y. Lee and J.-M. Nam, *Nano Lett.*, 2018, **18**, 7419.

56 D.-K. Lim, K.-S. Jeon, H. M. Kim, J.-M. Nam and Y. D. Suh, *Nat. Mater.*, 2010, **9**, 60–67.

57 D.-K. Lim, K.-S. Jeon, J.-H. Hwang, H. Kim, S. Kwon, Y. D. Suh and J.-M. Nam, *Nat. Nanotechnol.*, 2011, **6**, 452–460.

